emstoPA (AgeTech UK) NeuroTech
Antidote to address possible intracranial bleeding during ischaemic stroke. The availability of a novel tPA-neutralising antidote to address possible intracranial bleeding caused by tPA, the current gold standard treatment for Ischemic Stroke, has the potential to save lives and reduce disability in multiple patients worldwide.
Technology:
AgeTech Companies
Industry:
UK AgeTech 2020
Headquarters:
United Kingdom
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership